N
UPB

Natixis’s Upstream Bio Inc UPB Stock Holding History

Natixis’s Portfolio UPB Stock Details UPB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.08K Buy
+120
New +$2.16K ﹤0.01% 1064

Other funds holding UPB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Natixis's UPB Position: Q1 2026 in Review

Natixis opened a new position in Upstream Bio Inc (UPB) in Q1 2026: 120 shares worth $1.08K. The stake represents ﹤0.01% of the portfolio and ranks #1064 among its holdings.

140 funds tracked by Wall St. Rank hold UPB as of Q1 2026.

  • Natixis held 120 shares of Upstream Bio Inc worth $1.08K as of Q1 2026.
  • Upstream Bio Inc was a new Natixis position in Q1 2026.
  • Upstream Bio Inc made up ﹤0.01% of Natixis's portfolio in Q1 2026, its #1064 holding.
  • 140 funds tracked by Wall St. Rank held Upstream Bio Inc as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.